InVivo Therapeutics Holdings Corp. (NVIV) today announced the
promotion of Lisa Crockett to Vice President, Regulatory and Kristin
Neff to Vice President, Clinical Operations. These promotions are
effective January 1, 2014.
Interim Chief Executive Officer Michael Astrue said, “These two
executives have been instrumental in our effort to put our first product
candidate into the clinic in the next few months. They have both also
demonstrated expertise and judgment with their work on InVivo’s evolving
pipeline.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company
with unique technologies for drug delivery with a focus on treatment of
spinal cord injuries. The Company was founded in 2005 with proprietary
technology co-invented by Robert Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
is affiliated with Massachusetts General Hospital. In 2011 the Company
earned the David S. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury
medicine. The publicly traded company is headquartered in Cambridge, MA.
For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. Any forward-looking statements
contained herein are based on current expectations, but are subject to a
number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include,
but are not limited to, risks and uncertainties relating to the
Company’s ability to obtain FDA approval of its revised protocol and the
timing thereof; the identification of appropriate clinical sites; the
Institutional Review Board process; the Company’s ability to enter into
partnerships; the Company’s ability to obtain FDA approval to
commercialize its products; the Company’s ability to develop, market and
sell products based on its technology; the expected benefits and
efficacy of the Company’s products and technology in connection with
spinal cord injuries; the availability of substantial additional funding
for the Company to continue its operations and to conduct research and
development, clinical studies and future product commercialization; and
other risks associated with the Company’s business, research, product
development, regulatory approval, marketing and distribution plans and
strategies identified and described in more detail in our filings with
the SEC, including our Form 10-K and 10-Qs and our current reports on
Form 8-K. We do not undertake to update these forward-looking statements
made by us.
Copyright Business Wire 2013